(ACHC) Acadia Healthcare - Overview
Stock: Inpatient Care, Outpatient Services, Residential Programs
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 63.9% |
| Relative Tail Risk | -11.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.53 |
| Alpha | -81.83 |
| Character TTM | |
|---|---|
| Beta | 0.645 |
| Beta Downside | 0.727 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.63% |
| CAGR/Max DD | -0.53 |
Description: ACHC Acadia Healthcare January 14, 2026
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) operates a network of behavioral-health facilities across the United States and Puerto Rico, including acute inpatient psychiatric hospitals, residential recovery and eating-disorder centers, comprehensive treatment hubs, and outpatient clinics. Founded in 2005 and headquartered in Franklin, Tennessee, the firm targets community-level mental-health and addiction services under the Health Care Facilities GICS sub-industry.
Key operating metrics that analysts watch include: (1) **Revenue growth** of roughly 6-8 % YoY in 2023, driven by higher occupancy and expanded Medicaid contracts; (2) **Average daily census (ADC)** hovering around 85 % of capacity, which is above the industry median of ~78 % and indicates strong demand; and (3) **EBITDA margin** stabilizing near 12 % after recent cost-optimization initiatives. The sector’s outlook is influenced by rising mental-health awareness, increasing insurance reimbursement rates for behavioral health, and a growing shortage of inpatient beds that pressures utilization rates upward.
For a deeper, data-driven dive into ACHC’s valuation assumptions and scenario analysis, you might find ValueRay’s platform worth exploring.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 107.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA 3.04 > 1.0 |
| NWC/Revenue: 7.04% < 20% (prev 1.36%; Δ 5.68% < -1%) |
| CFO/TA 0.05 > 3% & CFO 334.9m > Net Income 107.4m |
| Net Debt (2.31b) to EBITDA (456.6m): 5.06 < 3 |
| Current Ratio: 1.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (90.6m) vs 12m ago -1.74% < -2% |
| Gross Margin: 81.42% > 18% (prev 0.42%; Δ 8099 % > 0.5%) |
| Asset Turnover: 53.17% > 50% (prev 53.19%; Δ -0.02% > 0%) |
| Interest Coverage Ratio: 2.08 > 6 (EBITDA TTM 456.6m / Interest Expense TTM 131.0m) |
Altman Z'' 0.88
| A: 0.04 (Total Current Assets 748.0m - Total Current Liabilities 517.9m) / Total Assets 6.41b |
| B: 0.06 (Retained Earnings 411.7m / Total Assets 6.41b) |
| C: 0.04 (EBIT TTM 272.5m / Avg Total Assets 6.14b) |
| D: 0.13 (Book Value of Equity 412.6m / Total Liabilities 3.12b) |
| Altman-Z'' Score: 0.88 = B |
Beneish M -3.52
| DSRI: 0.98 (Receivables 502.8m/489.2m, Revenue 3.27b/3.12b) |
| GMI: 0.52 (GM 81.42% / 42.34%) |
| AQI: 0.93 (AQ_t 0.38 / AQ_t-1 0.41) |
| SGI: 1.05 (Revenue 3.27b / 3.12b) |
| TATA: -0.04 (NI 107.4m - CFO 334.9m) / TA 6.41b) |
| Beneish M-Score: -3.52 (Cap -4..+1) = AAA |
What is the price of ACHC shares?
Over the past week, the price has changed by -0.52%, over one month by -10.03%, over three months by -34.01% and over the past year by -68.70%.
Is ACHC a buy, sell or hold?
- StrongBuy: 9
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ACHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 19.1 | 42.6% |
| Analysts Target Price | 19.1 | 42.6% |
| ValueRay Target Price | 10 | -24.9% |
ACHC Fundamental Data Overview February 03, 2026
P/E Forward = 6.5317
P/S = 0.3722
P/B = 0.3896
P/EG = 1.32
Revenue TTM = 3.27b USD
EBIT TTM = 272.5m USD
EBITDA TTM = 456.6m USD
Long Term Debt = 2.28b USD (from longTermDebt, last quarter)
Short Term Debt = 46.9m USD (from shortTermDebt, last quarter)
Debt = 2.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.31b USD (from netDebt column, last quarter)
Enterprise Value = 3.52b USD (1.22b + Debt 2.43b - CCE 118.7m)
Interest Coverage Ratio = 2.08 (Ebit TTM 272.5m / Interest Expense TTM 131.0m)
EV/FCF = -10.15x (Enterprise Value 3.52b / FCF TTM -347.2m)
FCF Yield = -9.85% (FCF TTM -347.2m / Enterprise Value 3.52b)
FCF Margin = -10.63% (FCF TTM -347.2m / Revenue TTM 3.27b)
Net Margin = 3.29% (Net Income TTM 107.4m / Revenue TTM 3.27b)
Gross Margin = 81.42% ((Revenue TTM 3.27b - Cost of Revenue TTM 606.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.55 (Enterprise Value 3.52b / Total Assets 6.41b)
Interest Expense / Debt = 1.51% (Interest Expense 36.6m / Debt 2.43b)
Taxrate = 4.17% (1.67m / 40.0m)
NOPAT = 261.1m (EBIT 272.5m * (1 - 4.17%))
Current Ratio = 1.44 (Total Current Assets 748.0m / Total Current Liabilities 517.9m)
Debt / Equity = 0.78 (Debt 2.43b / totalStockholderEquity, last quarter 3.12b)
Debt / EBITDA = 5.06 (Net Debt 2.31b / EBITDA 456.6m)
Debt / FCF = -6.65 (negative FCF - burning cash) (Net Debt 2.31b / FCF TTM -347.2m)
Total Stockholder Equity = 3.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.75% (Net Income 107.4m / Total Assets 6.41b)
RoE = 3.49% (Net Income TTM 107.4m / Total Stockholder Equity 3.08b)
RoCE = 5.08% (EBIT 272.5m / Capital Employed (Equity 3.08b + L.T.Debt 2.28b))
RoIC = 4.96% (NOPAT 261.1m / Invested Capital 5.26b)
WACC = 3.73% (E(1.22b)/V(3.64b) * Re(8.29%) + D(2.43b)/V(3.64b) * Rd(1.51%) * (1-Tc(0.04)))
Discount Rate = 8.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.70%
Fair Price DCF = unknown (Cash Flow -347.2m)
EPS Correlation: -52.43 | EPS CAGR: -44.38% | SUE: -2.41 | # QB: 0
Revenue Correlation: 95.71 | Revenue CAGR: 10.11% | SUE: 0.35 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.30 | Chg30d=-0.043 | Revisions Net=-5 | Analysts=10
EPS next Year (2026-12-31): EPS=1.74 | Chg30d=-0.233 | Revisions Net=-7 | Growth EPS=-12.2% | Growth Revenue=+3.2%